Dinesen Birthe, Dam Gade Josefine, Skov Schacksen Cathrine, Spindler Helle, Eie Albertsen Andi, Dittmann Lars, Jochumsen Mads, Svenstrup Møller Dorthe
Department of Health Science and Technology, Laboratory for Welfare Technology - Telehealth & Telerehabilitation, Sport Sciences - Performance and Technology, Aalborg University, Aalborg East Denmark, Denmark.
Department of Psychology and Behavioral Sciences, Aarhus University, Aarhus, Denmark.
JMIR Cardio. 2021 Jul 19;5(2):e27321. doi: 10.2196/27321.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is predicted to more than double in prevalence over the next 20 years. Tailored patient education is recommended as an important aspect of AF care. Current guidelines emphasize that patients become more active participants in the management of their own disease, yet there are no rehabilitation programs for patients with AF in the Danish health care system. Through participatory design, we developed the Future Patient Telerehabilitation (TR) Programs, A and B, for patients with AF. The 2 programs are based on HeartPortal and remote monitoring, together with educational modules.
The aim of this pilot study is to evaluate and compare the feasibility of the 2 programs of TR for patients with AF.
This pilot study was conducted between December 2019 and March 2020. The pilot study consisted of testing the 2 TR programs, A and B, in two phases: (1) treatment at the AF clinic and (2) TR at home. The primary outcome of the study was the usability of technologies for self-monitoring and the context of the TR programs as seen from patients' perspectives. Secondary outcomes were the development of patients' knowledge of AF, development of clinical data, and understanding the expectations and experiences of patients and spouses. Data were collected through interviews, questionnaires, and clinical measurements from home monitoring devices. Statistical analyses were performed using the IBM SPSS Statistics version 26. Qualitative data were analyzed using NVivo 12.0.
Through interviews, patients articulated the following themes about participating in a TR program: usefulness of the HeartPortal, feeling more secure living with AF, community of practice living with AF, and measuring heart rhythm makes good sense. Through interviews, the spouses of patients with AF expressed that they had gained increased knowledge about AF and how to support their spouses living with AF in everyday life. Results from the responses to the Jessa AF Knowledge Questionnaire support the qualitative data, as they showed that patients in program B acquired increased knowledge about AF at follow-up compared with baseline. No significant differences were found in the number of electrocardiography recordings between the 2 groups.
Patients with AF and their spouses were positive about the TR program and they found the TR program useful, especially because it created an increased sense of security, knowledge about mastering their symptoms, and a community of practice linking patients with AF and their spouses and health care personnel. To assess all the benefits of the Future Patient-TR Program for patients with AF, it needs to be tested in a comprehensive randomized controlled trial.
ClinicalTrials.gov NCT04493437; https://clinicaltrials.gov/ct2/show/NCT04493437.
心房颤动(AF)是最常见的心律失常,预计在未来20年其患病率将增加一倍以上。推荐进行个性化患者教育,作为房颤护理的一个重要方面。当前指南强调患者应更积极地参与自身疾病的管理,但丹麦医疗保健系统中没有针对房颤患者的康复项目。通过参与式设计,我们为房颤患者开发了未来患者远程康复(TR)项目A和B。这两个项目基于心脏门户和远程监测,并配有教育模块。
本试点研究的目的是评估和比较这两个TR项目对房颤患者的可行性。
本试点研究于2019年12月至2020年3月进行。该试点研究包括分两个阶段测试TR项目A和B:(1)在房颤诊所治疗,(2)在家进行TR。该研究的主要结果是从患者角度看自我监测技术的可用性和TR项目的背景情况。次要结果包括患者房颤知识的发展、临床数据的发展,以及了解患者及其配偶的期望和体验。通过访谈、问卷调查以及家庭监测设备的临床测量收集数据。使用IBM SPSS Statistics 26版进行统计分析。使用NVivo 12.0分析定性数据。
通过访谈,患者阐述了参与TR项目的以下主题:心脏门户的有用性、房颤患者生活更安心、房颤患者的实践社区,以及测量心律很有意义。通过访谈,房颤患者的配偶表示他们对房颤以及如何在日常生活中支持患房颤的配偶有了更多了解。对杰萨房颤知识问卷的回答结果支持了定性数据,因为结果显示项目B中的患者在随访时相比基线对房颤有了更多了解。两组之间心电图记录数量没有显著差异。
房颤患者及其配偶对TR项目持积极态度,他们发现TR项目很有用,特别是因为它增强了安全感、增加了对症状的掌控知识,并创建了一个将房颤患者及其配偶与医护人员联系起来的实践社区。为评估未来患者TR项目对房颤患者的所有益处,需要在全面的随机对照试验中进行测试。
ClinicalTrials.gov NCT04493437;https://clinicaltrials.gov/ct2/show/NCT04493437